Skip to main content

TCG Crossover — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

76
Companies
$14.2B
Total invested
$173.4M
Avg. check
13
Industries
Biotechnology 24Health Care 15Therapeutics 15Medical 12Pharmaceutical 9Biopharma 6+7 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 76
Mirum Pharmaceuticals
December 2025

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.

Biotechnology · Foster City$68.5M Post Ipo Equity
Structure Therapeutics
December 2025

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

Biotechnology · South San Francisco$747.5M Post Ipo Equity
Cogent Biosciences
November 2025

Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.

Biotechnology · Waltham$200.0M Post Ipo Debt
Rapt Therapeutics
October 2025

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

Biotechnology · South San Francisco$250.0M Post Ipo Equity
ADC Therapeutics
October 2025

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

Biopharma · Lausanne$60.0M Post Ipo Equity
Affinia Therapeutics
October 2025

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Biotechnology · Waltham$40.0M Series C
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Maze Therapeutics
September 2025

Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.

Biopharma · South San Francisco$150.0M Post Ipo Equity
Mineralys Therapeutics
September 2025

Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.

Biopharma · Radnor$287.5M Post Ipo Equity
Korsana Biosciences
September 2025

Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.

Biopharma · Waltham$150.0M Series A
Plexium
August 2025

Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.

Biotechnology · San Diego$60.1M Series C
Abivax
July 2025

Abivax develops medicines that alter the body's natural immune system mechanisms.

Biotechnology · Paris$747.5M Post Ipo Equity
Arbor Biotechnologies
March 2025

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

Artificial Intelligence (AI) · Cambridge$73.9M Series C
ADARx Pharmaceuticals
February 2025

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Biotechnology · San DiegoSeries Unknown
Inhibrx
January 2025

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

Biotechnology · La Jolla$150.0M Post Ipo Debt
ADCendo
November 2024

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

Biotechnology · Copenhagen$135.0M Series B
Avalo Therapeutics
November 2024

Avalo Therapeutics is a clinical-stage biopharmaceutical company.

Biotechnology · Rockville$69.4M Post Ipo Equity
Vicebio
September 2024

Vicebio is a biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology.

Biotechnology · London$100.0M Series B
Pathalys Pharma
August 2024

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.

Biopharma · Raleigh$105.0M Series B
Entrada Therapeutics
June 2024

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Biotechnology · Boston$100.0M Post Ipo Equity
Tourmaline Bio
January 2024

Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.

Biotechnology · New York$172.5M Post Ipo Equity
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post Ipo Equity
Upstream Bio
June 2023

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.

Biotechnology · Waltham$200.0M Series B
Alkeus Pharmaceuticals
June 2023

Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.

Biotechnology · Cambridge$150.0M Series B

Where TCG Crossover invests

Biotechnology24
Health Care15
Therapeutics15
Medical12
Pharmaceutical9
Biopharma6

About TCG Crossover's portfolio

How many companies has TCG Crossover invested in?

TCG Crossover has invested in 76 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does TCG Crossover invest in?

TCG Crossover's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 13 different industry categories.

What is TCG Crossover's largest investment?

Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post Ipo Equity round. TCG Crossover's total known invested capital is $14.2B.

What is the average investment size for TCG Crossover?

TCG Crossover's average investment size is $173.4M across its portfolio of 76 companies.

What are TCG Crossover's most recent investments?

Recent TCG Crossover portfolio additions include Mirum Pharmaceuticals, Structure Therapeutics, Cogent Biosciences, Rapt Therapeutics, ADC Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 76 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →